Seeking to remake corporate America, a nonprofit has released a ranking of the largest publicly traded companies in the U.S. It is based on issues that its own polling finds are important to the public, such as worker pay and treatment, customer respect, and product quality, among many other things.
And while drug makers did not rate in the very highest positions, seven of these companies did fall within the Top 100, starting with Eli Lilly (LLY) at number 28. The others are Biogen (BIIB), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Celgene (CELG), Merck (MRK), and AbbVie (ABBV). All totaled, 1,000 companies were ranked, and 42 drug companies made the list.
The ranking was done by JUST Capital, which is the brainchild of Paul Tudor Jones, who founded a $10 billion hedge fund called Tudor Investment. The goal is to maintain an information clearinghouse that can be used to prod companies to make improvements while at the same time giving the public tools to make more informed decisions about purchasing, investing, and employment.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect